주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
심혈관계
여성건강
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
International Liver Congress (ILC) 2021
23 June - 26 June, 2021, United States
Adding amoxicillin/clavulanate to prednisolone yields no survival benefit in severe alcoholic hepatitis
2021-12-17
The addition of amoxicillin/clavulanate to prednisolone does not extend survival among patients with severe alcoholic hepatitis, though it may reduce infection risk, according to a French study presented at ILC 2021.
New liver dialysis device ? how safe in cirrhosis?
2021-12-17
A novel liver dialysis device appeared safe vs standard of care (SoC) in patients with acute on chronic liver failure (ACLF) in a small randomized study in Europe.
Phase II trial updates underpin benefit of efruxifermin for NASH
2021-12-17
In individuals with biopsy-confirmed nonalcoholic steatohepatitis (NASH) with fibrosis, the reductions in liver fat content (LFC) with efruxifermin correlated with improvements in markers of liver injury, fibrosis, metabolic parameters, and histologic features, according to updates from the phase IIa BALANCED study presented at ILC 2021.
Phase III data support resmetirom potential for NAFLD/NASH
2021-12-17
In individuals with nonalcoholic fatty liver disease (NAFLD) or presumed nonalcoholic steatohepatitis (NASH), resmetirom, an investigational, once-daily, oral selective thyroid hormone receptor beta agonist, significantly improved several hepatic and cardiovascular (CV) parameters, according to the findings of the phase III MAESTRO-NAFLD1 trial presented at ILC 2021.
Tenofovir alafenamide may prevent HBV mother-to-child transmission
2021-12-17
Tenofovir alafenamide (TAF), administered during the second or third trimester of pregnancy, may prevent mother-to-child transmission (MTCT) of hepatitis B virus (HBV) infection, according to two studies presented as posters at ILC 2021.
Tenofovir tied to lower risk of severe COVID-19 in HBV patients
2021-12-17
Patients with chronic hepatitis B virus (HBV) infection who were treated with tenofovir had a lower risk of developing severe COVID-19 illness than those treated with entecavir, according to a study presented at the EASL International Liver Congress (ILC) 2021.
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
